anti-APRIL antibody

An anti-APRIL antibody is a monoclonal antibody designed to target and neutralize A Proliferation-Inducing Ligand (APRIL, also known as TNFSF13). APRIL is a member of the tumor necrosis factor (TNF) superfamily that plays a critical role in B-cell development, survival, and immunoglobulin class-switching (particularly to IgA). By binding to APRIL, these antibodies block its interaction with its receptors, B-cell maturation antigen (BCMA) and transmembrane activator and CAML interactor (TACI), thereby suppressing the survival of plasma cells and the production of pathogenic immunoglobulins. Anti-APRIL antibodies are primarily being developed for the treatment of IgA nephropathy (IgAN), multiple myeloma, and other B-cell-mediated autoimmune and inflammatory diseases. Additionally, preclinical research suggests that targeting APRIL can modulate lipid metabolism, leading to reduced circulating triglyceride levels and potential therapeutic benefits in hypertriglyceridemia and atherosclerosis.